- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01843790
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
August 31, 2015 updated by: La Jolla Pharmaceutical Company
A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
The primary objective of this study is to compare the change in estimated glomerular filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment.
The secondary objective is to determine the safety and tolerability of GCS-100 administered for 8 weeks relative to placebo.
In addition, the study will measure the effect of GCS-100 on circulating galectin-3 and other markers of disease activity.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Galectin-3 contributes to fibrosis, is elevated in patients with ESRD, and correlates with adverse outcomes (de Boer et.
al., 2011, Dang et.
al., 2012, Fernandes Bertocchi et.
al., 2008, Henderson et.
al., 2008).
Animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney (Dang et.
al., 2012, Fernandes Bertocchi et.
al., 2008, Henderson et.
al., 2008).
GCS-100 is a galectin- 3 antagonist that has been shown to reduce fibrosis pre-clinically.
Based on the role of galectin-3 and fibrosis in kidney disease, the Sponsor believes GCS-100 may be effective at treating patients with CKD.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85284
- Southwest Clinical Research Institute, LLC
-
-
California
-
La Mesa, California, United States, 91942
- California Institute of Renal Research
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Denver Nephrology
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Clinical Advancement Center, PLLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent
- Subject is ≥18 and ≤75 years of age; patients >75 years old may be included at the request of the investigator and discretion of the Medical Monitor
- Subject has an eGFR of 15 - 44 mL/min/1.73m2 determined using the 4-variable Modification of Diet in Renal Disease (MDRD) equation (see Section 10.1)
- Patients with CKD diagnosis >12 months and stable, in the opinion of the investigator, within the past 3 months
- Subject is willing and able to comply with all protocol requirements
- Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least 1 year) and male subjects with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the study period
Exclusion Criteria:
- Treatment with an experimental (unlicensed) drug within 4 weeks or ≤5 half-lives prior to screening
- Kidney disease due to systemic lupus erythematosus (regardless of whether active or in remission), any form of vasculitis (regardless of whether active or in remission), IgA nephropathy, multiple myeloma, polycystic kidney disease, untreated obstructed nephropathy or any other causes that, in the opinion of the investigator, may put the subject at an increased risk
- Planned renal replacement therapy of any kind within 6 months of randomization
- Previous solid organ transplant
- Systolic blood pressure ≤90 mmHg and ≥160 mmHg and diastolic blood pressure ≤40 mmHg and ≥100 mmHg at screening
Subject has clinical laboratory values of:
- Hemoglobin: ≤9 g/dL
- Total bilirubin: >1.5X the upper limit of normal (ULN)
- ALT and/or AST: >2.5X ULN
- Current treatment with immunosuppressive agents, except for topical agents or inhaled steroids when conditions are chronic and stable
- Treatment with any form of IV iron therapy within 4 weeks prior to screening
- Known history of cancer (excluding non-melanoma skin cancer that is not being actively treated) within 5 years of screening
- Known history of human immunodeficiency virus, active hepatitis C virus (HCV), active hepatitis B virus (HBV), or prior history of infection with HBV (HBcAb positive); if adequate hepatic function has been documented for patients with HCV or prior history of hepatitis B without evidence of cirrhosis, the Medical Monitor may approve their enrollment
- Clinically relevant active infection and/or a serious co-morbid medical condition, such as recent myocardial infarction (within the last 6 months), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, severe or uncontrolled chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.
- Subject had major surgery within 4 weeks of randomization
- If female, subject is pregnant or breastfeeding
- Subject has a concomitant disease or condition, including laboratory abnormalities, which, in the opinion of the investigator, could interfere with the conduct of the study or put the subject at unacceptable risk
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo, saline
Saline, dosed weekly for 8 weeks
|
The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height.
The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP.
Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
Other Names:
|
Experimental: GCS-100 low dose
Low dose of GCS-100 given IV once per week for 8 weeks
|
The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height.
The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP.
Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
|
Experimental: GCS-100 high dose
High dose of GCS-100 given IV once per week for 8 weeks
|
The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height.
The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP.
Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in estimated glomerular filtration rate (eGFR) from baseline relative to placebo after administration of GCS-100 for 8 weeks in patients with chronic kidney disease (CKD) and baseline eGFR of 15 - 44 mL/min/1.73m2
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events as a measure of safety and tolerability of GCS-100 administered for 8 weeks relative to placebo in patients with CKD
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: George Tidmarsh, MD, PhD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
February 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
April 25, 2013
First Submitted That Met QC Criteria
April 30, 2013
First Posted (Estimate)
May 1, 2013
Study Record Updates
Last Update Posted (Estimate)
September 1, 2015
Last Update Submitted That Met QC Criteria
August 31, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCS-100-CS-4002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Placebo, Saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Children's Hospital Los AngelesThrasher Research Fund; UCSF Benioff Children's Hospital OaklandCompleted
-
University of OxfordUniversity of BirminghamTerminatedTuberculosisUnited Kingdom
-
University of Texas Southwestern Medical CenterCompletedAcute BronchiolitisUnited States
-
University of MichiganRadiological Society of North AmericaTerminated
-
AstraZenecaGynecologic Oncology Group Foundation; European Network for Gynaecological...RecruitingLocally Advanced Cervical CancerSpain, Denmark, Italy, Korea, Republic of, Japan, Peru, China, Brazil, Taiwan, United States, Canada, Turkey, India, Poland, Mexico, Puerto Rico, Norway
-
University of CincinnatiUnited States Department of DefenseRecruitingMeniscus TearUnited States
-
Indiana Hand to Shoulder CenterCTM BiomedicalEnrolling by invitationOsteoarthritis | Osteoarthritis Thumb Base Joint | Carpometacarpal Osteoarthritis | ThumbUnited States
-
Dr. med. Mahir KarakasCompleted
-
Noveome Biotherapeutics, formerly StemnionTerminatedDiabetes | Third Degree BurnsUnited States